Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's second consecutive day of losses.

According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...

Lockheed Martin ( NYSE: LMT) and Rolls Royce (LON: RR) Allen views this as one of the megatrends of the next five years, with ...

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow ...

Vertex Energy Inc (VTNR) stock saw a modest uptick, ending the day at $0.4 which represents a slight increase of $0.05 or 14.29% from the prior close of $0.35. The stock opened at $0.35 and touched a ...

Discover why Vertex stock is undervalued with the potential of VX-548 as a groundbreaking pain treatment drug in the ...